Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera Correction Study in Hemodialysis Patients
NCT00433693Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2007
- Primary completion
- Mar 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Epoetin alfa RB in anemia of chronic kidney disease, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Ratio of patients whose Hb concentration reach >= 10.0g/dL and increasing amount of Hb concentration reach >= 1.0g/dL at 26 weeks. Started Feb 2007; status: completed.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT00433693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433693.